Researchers from Shanghai Center for System Biomedicine and Ruijin Hospital, School of Medicine at SJTU find a plurality of high specificity and sensitivity serum marker for gastric carcinoma. Research findings was published online in Molecular & cellular proteomics (MCP), a professional journal on Proteomics.
According to statistics provided by WTO, number of new cases in gastric carcinoma reached 952,000 globally in 2012, causing 723,000 deaths. Morbidity and Mortality of gastric carcinoma ranked 2nd and 3rd respectively among all the malignant tumors. In China, every second witnessed 3 deaths in gastric carcinoma. According to the statistics provided by Ruijin Hospital from School of Medicine, in recent three decades, survival rate of gastric carcinoma patients exceeded 90% five years after early treatment, while less than 10% of the patients survived after late treatment. It is evident that early treatment for gastric carcinoma is of great significance. However, commonly used tumor markers for gastric carcinoma, for example Carcino Embryonie Antigen (hereinafter referred to as CEA) are weak in specificity and sensitivity, new platform for screening diagnosis markers is in urgent need.
With high flux and its availability in parallel analysis, protein chip is particularly suitable for the research on serum marker for tumors and immune-related diseases. Researchers used human protein chips which covered approximately 17,000 kinds of protein to analyze the serum of 37 gastric carcinoma patients and 50 healthy people, and found 44 kinds of autoantibody with differential expression. The second round screening was based on customized protein chips extracted from above-mentioned antibody. The experiment covered serum from 300 gastric carcinoma patients, 314 gastric carcinoma patients with high risk and 300 healthy people, and got 7 biomarker candidates. Researchers then conducted ELISA test on serum from 300 gastric carcinoma patients and 300 healthy people. The 7 serum marker for gastric carcinoma, screened by researchers exceeded traditional single or mixed markers diagnosis (CEA, CA25, CA72-4, CA99) commonly used in clinic, no matter in sensitivity, specificity or accuracy. This research finding is of great clinical value in gastric carcinoma screening and early diagnosis.
The research process of protein chip-based serum marker is also applicable for the finding of serum biomarkers for other tumors and immune-related diseases. Serum biomarkers found by researchers is of huge industrial potential in both early diagnosis and prognostic prediction of gastric carcinoma. This research program has already obtained 7 issued patents. Researchers are establishing cooperation with business and attempting to convert the finding into practice and bring benefit to gastric carcinoma patients.
This research program is sponsored by National Hi-tech R&D Program (Program 863) and National Natural Science Foundation of China. Dr. YANG Lina, Associate Prof. WANG Jingfang from Shanghai Center for System Biomedicine and Dr. LI Jianfang from Ruijin Hospital are co-authors of the research paper. TAO Shengce, researcher from Shanghai Center for System Biomedicine and LIU Bingya, research from Ruijin Hospital are co-corresponding authors of the paper. TAO Shengce focuses on the development and application of protein chip technology, he established technology platform for protein chips and conducted medicine-related researches in systematic manner.